Friday, June 10, 2022

Filament Health (FLHLF)
Collaboration Formed To Develop Additional Botanical Compounds

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Filament Forms Collaboration With Jaguar Health.  Filament and Jaguar Health (JAGX, $0.35, Not Rated) have signed a Letter of Intent to develop botanical compounds for psychiatric uses.  We believe Filament’s expertise in extraction and manufacturing technologies fits well with Jaguar’s extensive research in botanical compounds. 

Research Collaboration Will Develop Products For Out-licensing.  The collaboration intends to develop psychoactive compounds for use in mental health indications, such as attention deficit hyperactivity disorder (ADHD), social anxiety disorder, and related conditions. The companies plan to license commercialization rights to drug candidates developed under the collaboration with an equal profit split….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.